Relief Therapeutics Holding AG (RLFTF)

[DaveV-1]

Info regarding negotiations status re: sale of ZYESAMI treatment to US DOD

Interesting Info from S4 of Big Rock SPAC and NeuroRX that impacts RLFTF and drug sales from pg 240, URL at the bottom

In April 2020, NeuroRx was invited to enter the Coronawatch Program, a competitive program maintained by the Biomedical Advanced Research and Development Authority (“BARDA”) of the US Department of Health and Human Services. In September 2020, NeuroRx was approached by Operation Warp Speed (“OWS”) and invited to enter into weekly collaborative meetings with OWS’ multifunctional Product Collaboration Team in order to refine plans for formulation, scaleup, packaging, storage, and stability of a potential commercial


240

Table of Contents

presentation of ZYESAMI. In October 2020, NeuroRx was invited to submit a proposal to a Broad Agency Announcement published by the Department of Defense Medical Countermeasures program. In November 2020, following review of the initial proposal, NeuroRx was awarded an Other Transactional Authority procurement by the Department of Defense Medical Countermeasures Program under which the US Government proposes to procure prototype courses of ZYESAMI sufficient to treat 30,000 patients. The OTA further requires that

NeuroRx provide scaleup plans for the potential manufacture of 100,000 treatment doses per calendar quarter commencing in the second quarter of 2021. NeuroRx submitted a final proposal in response to the OTA in December 2020 and has been advised that the procurement is currently under technical review, pending results of the phase 2b/3 clinical trial that will complete its primary endpoint period in late January 2021. Should these data fail show evidence of efficacy in treating Critical COVID-19, NeuroRx believes it likely that DOD will not award funding under the OTA. Should a procurement be funded and should NeuroRx derive profit from the revenues of such procurement, NeuroRx is obligated to share that profit equally with Relief Therapeutics.

https://www.sec.gov/Archives/edgar/data/1719406/000119312521019278/d56937ds4.htm